Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer

October 01, 2019
LU005
Lung Cancer
Brian Myre, MD
Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

This phase II/III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer. Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving chemoradiation with or without atezolizumab may work better in treating patients with limited stage small cell lung cancer.

Sponsor: NRG Oncology

https://clinicaltrials.gov/ct2/show/NCT03811002

  • Patients with a pleural effusion will be eligible if thoracentesis is negative and non-bloody or if pleural fluid is too small to effectively sample 
  • Not pregnant
  • No metastatic disease
  • No surgical resection of small cell lung cancer
  • No prior invasive malignancy unless disease free for a minimum of 2 years 
  • No more than 1 cycle of platinum-based chemotherapy for SCLC or prior radiotherapy to the lungs or mediastinum prior to enrollment 
  • No severe, active co-morbidity

6 years

Accepting Participants
Interventional
II/III
Kathy Seymour, BSN
630-646-6075
630-646-6110
630-646-6072